US Patent

US9211291 — Treatment regimen utilizing neratinib for breast cancer

Method of Use · Assigned to Wyeth LLC · Expires 2030-03-24 · 4y remaining

Vulnerability score 51/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an extended treatment regimen for HER-2/neu overexpressed/amplified cancer patients using neratinib therapy.

USPTO Abstract

An extended regimen for treatment of HER-2/neu overexpressed/amplified cancer is described, with involves delivering a course of neratinib therapy to HER-2/neu overexpressed/amplified cancer patients following the completion of surgical and adjuvant therapy. The neratinib regimen may be continued for upwards of twelve months to five years. Also provided are pharmaceutical kits designed to facilitate compliance with the regimen.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2043 — neratinib-maleate

Patent Metadata

Patent number
US9211291
Jurisdiction
US
Classification
Method of Use
Expires
2030-03-24
Drug substance claim
No
Drug product claim
No
Assignee
Wyeth LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.